ES
BBOT

Enavate Sciences’s BridgeBio Oncology BBOT Stock Holding History

Enavate Sciences’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20M Hold
2,626,946
– – 5.8% 4
2026
Q1 		$23.5M Hold
2,626,946
– – 6.69% 5
2025
Q4 		$32.9M Hold
2,626,946
– – 6.49% 6
2025
Q3 		$30.4M Buy
+2,626,946
New +$27.4M 9.29% 5

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Enavate Sciences's BBOT Position: Q2 2026 in Review

Enavate Sciences held its BridgeBio Oncology (BBOT) position steady in Q2 2026 at 2,626,946 shares worth $20M. The position accounts for 5.8% of the portfolio, ranked #4.

Enavate Sciences first reported a position in BBOT in Q3 2025 and has held it in 4 quarters since. The position peaked at $32.9M in Q4 2025. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Enavate Sciences held 2,626,946 shares of BridgeBio Oncology worth $20M as of Q2 2026.
  • Enavate Sciences left its BridgeBio Oncology share count unchanged in Q2 2026.
  • BridgeBio Oncology made up 5.8% of Enavate Sciences's portfolio in Q2 2026, its #4 holding.
  • Enavate Sciences first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 4 quarters since.
  • Enavate Sciences's BridgeBio Oncology position peaked at $32.9M in Q4 2025.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Enavate Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.